1. Search Result
Search Result
Results for "

Eukaryotic Initiation Factor (eIF)

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Natural
Products

20

Recombinant Proteins

39

Antibodies

1

Oligonucleotides

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-108666
    ATPγS tetralithium salt
    1 Publications Verification

    Adenosine-5'-O-3-thiotriphosphate tetralithium salt; Adenosine 5'-[γ-thio]triphosphate tetralithium salt

    Eukaryotic Initiation Factor (eIF) P2Y Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis .
    ATPγS tetralithium salt
  • HY-13251
    Silvestrol
    50+ Cited Publications

    (-)-Silvestrol

    Eukaryotic Initiation Factor (eIF) Apoptosis Autophagy Cancer
    Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from Agave americana Linn.. Silvestrol induces autophagy and caspase-mediated apoptosis .
    Silvestrol
  • HY-125021
    2BAct
    3 Publications Verification

    Eukaryotic Initiation Factor (eIF) Neurological Disease
    2BAct is a highly selective, orally active, and CNS-penetrant eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495) .
    2BAct
  • HY-15969
    Sal003
    4 Publications Verification

    Phosphatase Apoptosis Cancer
    Sal003 is a potent, specific and cell-permeable inhibitor of the eukaryotic translation initiation factor 2α (eIF2α) phosphatase. Sal003 is a derivative of salubrinal .
    Sal003
  • HY-19356A

    Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    Didesmethylrocaglamide, a derivative of Rocaglamide, is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. Didesmethylrocaglamide has potent growth-inhibitory activity with an IC50 of 5 nM. Didesmethylrocaglamide suppresses multiple growth-promoting signaling pathways and induces apoptosis in tumor cells. Antitumor activity .
    Didesmethylrocaglamide
  • HY-149555

    Eukaryotic Initiation Factor (eIF) Neurological Disease
    DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases .
    DNL343
  • HY-153399A

    ABBV-CLS-7262 THAM sodium

    Eukaryotic Initiation Factor (eIF) Neurological Disease Cancer
    Fosigotifator (ABBV-CLS-7262) THAM sodium is a brain penetrant, orally active EIF2b (eukaryotic initiation factor) activator. Fosigotifator THAM sodium stabilizes the elF2B complex and boosts the activity, including that of complexes carrying pathogenic vanishing white matter (VWM) mutations. Fosigotifator THAM sodium is an integrated stress response inhibitor (ISRI). Fosigotifator THAM sodium can be used for amyotrophic lateral sclerosis research .
    Fosigotifator THAM sodium
  • HY-16366

    ON 014185

    Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis Cancer
    Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors .
    Briciclib
  • HY-101785
    eIF4A3-IN-2
    1 Publications Verification

    Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM .
    eIF4A3-IN-2
  • HY-33838

    Eukaryotic Initiation Factor (eIF) Others
    eIF4A3-IN-8 serves as a negative control targeting eukaryotic initiation factor 4A3 (eIF4A3), with an IC50 > 100 μM; it exhibits no significant activity .
    eIF4A3-IN-8
  • HY-145262

    Eukaryotic Initiation Factor (eIF) Cancer
    eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e) with an IC50 of 13 nM. eIF4E-IN-2 inhibits MDA-MB-361 cells proliferation. eIF4E-IN-2 can be used for the study of breast cancer .
    eIF4E-IN-2
  • HY-147832

    Eukaryotic Initiation Factor (eIF) Cancer
    EIF2α activator 2 (Compound 1) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 2 exhibits high potency in SRB cell proliferation assays (IC50=0.46 μM). EIF2α activator 2 exhibits antiproliferative activity againist K562 and PBMC cells with IC50s of 4.79 and 10.52 μM, respectively .
    EIF2α activator 2
  • HY-176844

    ADC Payload Drug Intermediate Cancer
    eIF4A-IN-1 intermediate (Compound 71E) is an intermediate of Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-1 intermediate can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
    eIF4A-IN-1 intermediate
  • HY-134361

    P2Y Receptor Eukaryotic Initiation Factor (eIF) Neurological Disease Metabolic Disease Inflammation/Immunology
    ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis .
    ATP-γ-S tetrasodium
  • HY-111522

    Sirtuin c-Myc Cancer
    RK-9123016 is a potent inhibitor of SIRT2. RK-9123016 inhibits the enzymatic activity of SIRT2 with an IC50 value of 0.18 µM but not other human sirtuin members including SIRT1 and SIRT3 at 100 µM. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression .
    RK-9123016
  • HY-176843

    Eukaryotic Initiation Factor (eIF) ADC Payload Cancer
    eIF4A-IN-2 (Compound 93) is an Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
    eIF4A-IN-2
  • HY-145360

    Eukaryotic Initiation Factor (eIF) Cancer
    eIF4A3-IN-6 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-6 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1) .
    eIF4A3-IN-6
  • HY-148664

    Eukaryotic Initiation Factor (eIF) Cancer
    eIF4E-IN-4 (Compound 33) is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E) with biochemical activity value of 95 nM. eIF4E-IN-4 inhibits cap-dependent mRNA translation with an IC50 value of 2.5 μM. eIF4E-IN-4 can be used for breast cancer, colon cancer, and head and neck cancer study .
    eIF4E-IN-4
  • HY-153399

    ABBV-CLS-7262

    Eukaryotic Initiation Factor (eIF) Neurological Disease
    Fosigotifator (ABBV-CLS-7262) is a brain penetrant, orally active EIF2b (eukaryotic initiation factor) activator. Fosigotifator stabilizes the elF2B complex and boosts the activity, including that of complexes carrying pathogenic vanishing white matter (VWM) mutations. Fosigotifator is an integrated stress response inhibitor (ISRI). Fosigotifator can be used for amyotrophic lateral sclerosis research .
    Fosigotifator
  • HY-129768

    Eukaryotic Initiation Factor (eIF) Cancer
    CMLD012072 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012072 can induce RNA clamping of eIF4A1 and eIF4A2 and possess potent anti-neoplastic activity .
    CMLD012072
  • HY-129767

    Eukaryotic Initiation Factor (eIF) Cancer
    CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .
    CMLD012612
  • HY-121722

    Amino Acid Derivatives Cancer
    Deoxyhypusine is an unusual amino acid formed during the posttranslational modification of eukaryotic translation initiation factor 5A (eIF-5A) by the enzyme deoxyhypusine hydroxylase (DOHH) .
    Deoxyhypusine
  • HY-129769

    Eukaryotic Initiation Factor (eIF) Cancer
    CMLD012073 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012073 inhibits the growth of NIH/3T3 cells with an IC50 of 10 nM. CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) .
    CMLD012073
  • HY-43913

    Eukaryotic Initiation Factor (eIF) Others
    (R)-eIF4A3-IN-2 is a less active enantiomer of eIF4A3-IN-2. eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM .
    (R)-eIF4A3-IN-2
  • HY-145359

    Eukaryotic Initiation Factor (eIF) Cancer
    eIF4A3-IN-5 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-5 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1) .
    eIF4A3-IN-5
  • HY-122039

    Amino Acid Derivatives Others
    Hypusine dihydrochloride is a natural amino acid found only in the eukaryotic translation initiation factor 5A (eIF-5A). Hypusine is formed by the transfer of the butylamine portion from spermidine to the ϵ-amino group of a specific lysine residue of eIF-5A precursor and by the hydroxylation at carbon 2 of the incoming 4-aminobutyl moiety .
    Hypusine dihydrochloride
  • HY-174720

    mRNA Inflammation/Immunology
    Human EIF2AK2 mRNA encodes the human eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2) protein, a serine/threonine protein kinase that is activated by autophosphorylation after binding to dsRNA. EIF2AK2 plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation.
    Human EIF2AK2 mRNA
  • HY-168326

    DNA/RNA Synthesis Microtubule/Tubulin Cancer
    Antiproliferative agent-64 (Compound 76) is an inhibitor for eukaryotic translation initiation factor 4E (eIF4E), that block the secondary structure of mRNA, thereby inhibiting protein translation. Antiproliferative agent-64 inhibits the 5' untranslated region (5'UTR) of c-Myc (c-myc 5'UTR) with an EC50 of 1.2 nM, inhibits 5'UTR encoding tubulin (tub 5'UTR) with an EC50 of 40 nM. Antiproliferative agent-64 inhibits the proliferation of MDA-MB-231 with an EC50 of 7 nM .
    Antiproliferative agent-64
  • HY-101785R

    Reference Standards Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    eIF4A3-IN-2 (Standard) is the analytical standard of eIF4A3-IN-2 (HY-101785). This product is intended for research and analytical applications. eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM .
    eIF4A3-IN-2 (Standard)
  • HY-184004

    MNK Eukaryotic Initiation Factor (eIF) Neurological Disease Cancer
    NUCC-0231068 is a MNK1 and MNK2 inhibitor with IC50 values of 8 nM and 7 nM, respectively. NUCC-0231068 inhibits the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) at Ser209, with an IC50 of 23 nM in its purified form and 17 nM in its D2B form. NUCC-0231068 can be used in studies related to glioblastoma .
    NUCC-0231068
  • HY-173172

    Eukaryotic Initiation Factor (eIF) Apoptosis c-Myc CDK Cancer
    MG-002 is an orally active eIF4A inhibitor. MG-002 non-productively traps the eukaryotic translation initiation factor 4A (eIF4A) onto RNA, hindering the recruitment and scanning of ribosomes, thereby inhibiting mRNA translation. MG-002 selectively inhibits the growth and metastasis formation of triple-negative breast cancer (TNBC) tumors and induces cell apoptosis. MG-002 significantly inhibits the protein expression of c-MYC and cyclin D1. MG-002 can be used for research on TNBC .
    MG-002
  • HY-108666R

    Adenosine-5'-O-(3-thiotriphosphate) tetralithium salt (Standard); Adenosine 5'-[γ-thio]triphosphate tetralithium salt (Standard)

    Reference Standards Eukaryotic Initiation Factor (eIF) P2Y Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    ATPγS tetralithium salt (Standard) is the analytical standard of ATPγS (tetralithium salt) (HY-108666). This product is intended for research and analytical applications. ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis .
    ATPγS tetralithium salt (Standard)
  • HY-16366A

    ON 014185 sodium

    Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis Cancer
    Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors .
    Briciclib sodium

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

 

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

 

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: